SCHEMBL10162260

SCHEMBL10162260

CC(=O)C12CCC(CNC(=O)c3cc(C(=O)NCc4ccc(F)c(OC(F)F)c4)nc4ncnn34)(CC1)CC2

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MBOAT4 Q96T53 2/20 0.36
MMP13 P45452 8/20 0.35
ADAMTS4 O75173 1/20 0.34
MMP3 P08254 1/20 0.34
LMNA P02545 3/20 0.33
MAPK1 P28482 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
ALDH1A1 P00352 2/20 0.33
RORC P51449 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
PDE2A O00408 1/20 0.32
MMP10 P09238 1/20 0.32
MMP9 P14780 1/20 0.32
MMP8 P22894 1/20 0.32
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
PTGES O14684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10162258 0.90 RIPK1 (0.39) MBOAT4MMP13ADAMTS4MMP3PDE2A
SCHEMBL10162242 0.89 MMP13 (0.39) MMP13ADAMTS4MMP3ALDH1A1MEN1
SCHEMBL10162172 0.89 MMP13 (0.37) MMP13ADAMTS4MMP3LMNAMAPK1
SCHEMBL10162212 0.88 MMP13 (0.43) MMP13ADAMTS4MMP3LMNAMAPK1
SCHEMBL10162259 0.88 PDE2A (0.41) MBOAT4MMP13LMNAMAPK1SMN1; SMN2
SCHEMBL10162240 0.88 MMP13 (0.48) MMP13ADAMTS4MMP3ALDH1A1MEN1
SCHEMBL10162252 0.87 MMP13 (0.40) MMP13MAPK1PDE2A
SCHEMBL10162262 0.86 SMN1; SMN2 (0.38) MMP13LMNAMAPK1SMN1; SMN2ALDH1A1
SCHEMBL10162263 0.86 MMP13 (0.45) MBOAT4MMP13ADAMTS4MMP3ALDH1A1
SCHEMBL10162270 0.84 ALDH1A1 (0.33) MMP13ADAMTS4MMP3LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 MBOAT4 2357/4885MMP13 1/4885ADAMTS4 38/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MBOAT4 2357/4885MMP13 1/4885ADAMTS4 38/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MBOAT4 2357/4885MMP13 1/4885ADAMTS4 38/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MBOAT4 2357/4885MMP13 1/4885ADAMTS4 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.